LLY


Company Update (NASDAQ:INCY): Incyte Corporation Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis

Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a …

Stock Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Enters Into Global Collaboration And Licensing Agreement With Eli Lilly and Co

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced a global collaboration and license agreement with Eli Lilly and Co (NYSE:LLY) to develop and commercialize products combining …

Stock Update (NASDAQ:INCY): Incyte Corporation’s and Eli Lilly’s Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study

Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an …

A Roundup of Our Top Stories in Healthcare From the Week

One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …

West Pharmaceuticals: A Little Giant In The Pharma Sector

West Pharmaceutical Services (WST) is an example of a good stock in a good sector. I like the health care sector in the …

Insuline: Significant Upside, Alternative Diabetes Play With A Population Based Cost-Reduction Platform In Diabetes

Big Picture Thesis: Since Afrezza’s approval MannKind’s (NASDAQ:MNKD) shares have declined more than 50% as enthusiasm for their partnership with Sanofi-Aventis (NYSE:SNY) has …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts